Literature DB >> 2478075

Anti-HIV activity of dextran sulphate as determined under different experimental conditions.

H Nakashima1, O Yoshida, M Baba, E De Clercq, N Yamamoto.   

Abstract

Dextran sulphate is a potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1). Its anti-HIV-1 activity has been investigated under varying experimental conditions. MT-4 cells were infected with HIV-1 at different multiplicities of infection (MOI), and treated with either dextran sulphate, 3'-azido-2',3'-dideoxythymidine (AZT), or anti-HIV-1 serum obtained from an ARC patient. Dextran sulphate suppressed HIV-1 replication (as monitored by viral antigen expression) when the MOI was 0.01 or 0.1. It was ineffective at an MOI of 1.0. The anti-HIV-1 serum was only partially effective at an MOI of 0.01 and ineffective at an MOI of 0.1 or 1.0. AZT proved effective at all three MOIs. Co-cultures of uninfected and HIV-1-infected MT-4 cells were protected against destruction by dextran sulphate at a concentration of 10 and 100 micrograms/ml. To fully suppress viral antigen expression a concentration of 100 micrograms/ml was needed. When used at this concentration, a 1-h contact of dextran sulphate with the cells during the virus adsorption period sufficed to suppress HIV-1 antigen expression. In this sense, dextran sulphate behaved like the anti-HIV-1 serum. Dextran sulphate also behaved like OKT-4A in that they both inhibited HIV-1 attachment to the MT-4 cells, whereas OKT-4 failed to do so. However, dextran sulphate did not affect the binding of OKT-4A to the cells. The present results support the concept that dextran sulphate owes its anti-HIV-1 activity mainly to inhibition of virus binding to its target cells. The anti-HIV-1 activity of dextran sulphate is highly dependent on its sulphate content.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2478075     DOI: 10.1016/0166-3542(89)90033-8

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  11 in total

1.  Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins.

Authors:  M Hosoya; J Balzarini; S Shigeta; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

2.  Effects of succinylated concanavalin A on infectivity and syncytial formation of human immunodeficiency virus.

Authors:  T Matsui; S Kobayashi; O Yoshida; S Ishii; Y Abe; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

Review 3.  Anti-AIDS drug development: challenges and strategies.

Authors:  P Mohan
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

4.  Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion.

Authors:  H Nakashima; M Masuda; T Murakami; Y Koyanagi; A Matsumoto; N Fujii; N Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

5.  Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds.

Authors:  P R Meylan; R S Kornbluth; I Zbinden; D D Richman
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

6.  Exploring First Interactions Between Ostreid Herpesvirus 1 (OsHV-1) and Its Host, Crassostrea gigas: Effects of Specific Antiviral Antibodies and Dextran Sulfate.

Authors:  Claire Martenot; Nicole Faury; Benjamin Morga; Lionel Degremont; Jean-Baptiste Lamy; Maryline Houssin; Tristan Renault
Journal:  Front Microbiol       Date:  2019-05-24       Impact factor: 5.640

7.  Highly potent anti-HIV-1 activity isolated from fermented Polygonum tinctorium Aiton.

Authors:  Yu Zhong; Yoshiyuki Yoshinaka; Tadahiro Takeda; Noriko Shimizu; Sayaka Yoshizaki; Yoshio Inagaki; Shinobu Matsuda; Gisho Honda; Nobutaka Fujii; Naoki Yamamoto
Journal:  Antiviral Res       Date:  2005-03-27       Impact factor: 5.970

Review 8.  The antiviral activity of iota-, kappa-, and lambda-carrageenan against COVID-19: A critical review.

Authors:  Andri Frediansyah
Journal:  Clin Epidemiol Glob Health       Date:  2021-06-29

9.  Fluorescence molecular painting of enveloped viruses.

Authors:  Christoph Metzner; Feliks Kochan; John A Dangerfield
Journal:  Mol Biotechnol       Date:  2013-01       Impact factor: 2.695

10.  Peptides derived from HIV-1 integrase that bind Rev stimulate viral genome integration.

Authors:  Aviad Levin; Zvi Hayouka; Markus Helfer; Ruth Brack-Werner; Assaf Friedler; Abraham Loyter
Journal:  PLoS One       Date:  2009-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.